Thank you for your interesting points about the mechanism of eosinophils in COPD exacerbation. It was noted that neither trial reported triggers of exacerbation. Would we expect there to be a difference in anti-IL5 effect based upon the type of exacerbation? Can we biologically define eosinophilic vs. non-eosinophilic exacerbations? It seems a biomarker for COPD exacerbation itself is key to finding the subpopulation that anti-IL5 therapy would have the greatest benefit in.
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.